Successful Treatment of Adult Cerebral Salt Wasting With Fludrocortisone

Hyponatremia following cerebral trauma has commonly been attributed to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Cerebral salt wasting (CSW) can lead to a similar clinical picture, for which treatment is not well defined.

Report of a Case. A 75-year-old man presented with a 3-week history of worsening ataxia following blunt head trauma in a motor vehicle crash 1 month earlier. His history included uncomplicated type 2 diabetes mellitus and hypertension, managed with rosiglitazone, 4 mg/d, and ramipril, 2.5 mg/d. The patient was confused and had marked truncal ataxia. Central venous pressure was low at 3 mm Hg, indicating volume depletion. Euvolemia and normotension were maintained following the discontinuation of both rosiglitazone and ramipril therapies.

A computed tomographic scan of the brain demonstrated acute and chronic bilateral frontoparietal subdural hematomas measuring up to 22 mm in the maximum dimension, with shift of the septum pellucidum to the right by 5 mm and subfalcine herniation. Findings from serum biochemical analysis demonstrated a serum sodium level of 123 mEq/L (137-146 mEq/L) (milliequivalents per liter to millimoles per liter and, for pro-brain natriuretic peptide (pro-BNP), picograms per milliliter to nanograms per liter are 1-to-1 conversions).

Changes in serum and urinary sodium concentration with treatment.

Figure. Changes in serum and urinary sodium concentration with treatment. For serum sodium, milliequivalents per liter to millimoles per liter and, for pro-brain natriuretic peptide (pro-BNP), picograms per milliliter to nanograms per liter are 1-to-1 conversions.

Comment. Both CSW and SIADH are associated with hyponatremia, hypouricemia, and inappropriately high urinary sodium concentration and osmolality. The only distinguishing features are signs of volume depletion. It has been postulated that CSW is a centrally mediated process, possibly via secretion of natriuretic peptides or disrupted sympathetic neural input to the proximal tubules. Serum N-terminal pro-brain natriuretic peptide level was not elevated in our case.

Scattered case reports in the pediatric population demonstrated suppressed plasma renin activity and plasma aldosterone concentration in CSW, while plasma aldosterone concentration usually remained normal or high in SIADH, although this is not a universal finding. While hyporeninemic hypaldosteronism can be a manifestation of renal tubulopathy in type 2 diabetes, prior normal findings from serum biochemical analysis excluded it as a preexisting contributing complication in our patient.

Fludrocortisone has been used to prevent ischemia in patients with subarachnoid hemorrhage, but its use in other cerebral pathologic conditions is poorly studied. Hyponatremia not responding to fluid restriction should raise the concern of undiagnosed CSW, which may be supported by excessive natriuresis and suppressed plasma renin activity and plasma aldosterone concentration. The lack of sustained response to hyper-
ontonic saline led to our empirical trial of fludrocortisone, which was later supported by the results of suppressed plasma renin activity and plasma aldosterone concentration. Early administration of fludrocortisone may alleviate the need of hypertonic saline infusion and shorten hospital stay.

In conclusion, we describe the biochemical changes in a case of CSW and its successful response to fludrocortisone therapy. Although the mechanism of inappropriate hyporeninemic hypoaldosteronism in CSW remains uncertain, and it may not be universal in all cases of CSW, the current case indicates that fludrocortisone therapy may be of benefit in selected adult patients with CSW and refractory hyponatremia.

Peter Lee, MBBS(Hons)
Graham R. D. Jones, PhD
Jacqueline R. Center, MBBS, FRACP, PhD

Correspondence: Dr Lee, Department of Endocrinology, St Vincent’s Hospital, 390 Victoria St, Darlinghurst NSW 2010, Australia (pccyllee@gmail.com).

Author Contributions: Study concept and design: Lee and Center. Acquisition of data: Lee and Jones. Analysis and interpretation of data: Lee, Jones, and Center. Drafting of the manuscript: Lee. Critical revision of the manuscript for important intellectual content: Lee, Jones, and Center. Administrative, technical, and material support: Lee and Jones.

Study supervision: Center.

Financial Disclosure: None reported.


COMMENTS & OPINIONS

Prevalence of Type 1 Gaucher Disease in the United States

The study by Landgren et al1 investigated the risk of malignancy in patients with type 1 Gaucher disease (GD). We have several questions about their article that address the validity of the findings. First, we are concerned by the large number of patients with reported type 1 GD. The prevalence of type 1 GD is 1:40000 to 60000 in the general population and 1:500 to 800 among Ashkenazi Jews.2,3 Recognizing that Ashkenazi Jews constitute no more than 2% to 3% of the US population, fewer than 200 patients with GD should be expected among 4.5 million Department of Veterans Affairs (VA) hospital patients. The authors found 1525. The authors attribute the high prevalence of GD to the study being hospital based. However, a national hospital-based study in Spain, using demographic, clinical, diagnostic, and radiological data for patient identification, found only 75 patients with GD—numbers even lower than those predicted from other European studies.

Second, the authors did not report how many of their patients (mean age at study entry, 51.1 years) had died. Because a 50-year-old patient with type 1 GD can expect to live an additional 27.2 years,3 most of the 1525 VA patients should be alive. However, only about 250 male US patients older than 50 years are enrolled in the International Gaucher Registry.4 It might be argued that the Registry enrollment favors patients with more severe phenotypes, whereas the VA patients identified by the authors have clinically mild disease. However, it seems to us unlikely that patients would be hospitalized without significant symptoms. Moreover, the probability that patients with mild GD will come to diagnosis in any medical setting is low. Only 1 of 5 North American hematologists suspected GD when presented with a hypothetical patient with 6 of its common signs and symptoms.5 Furthermore, more than 250 glucocerebrosidase gene mutations and polymorphisms have been identified, and those associated with mild as well as more severe phenotypes have been well characterized in terms of their population frequencies.6 It seems unlikely that a unique, sizeable population of mildly affected patients with type 1 GD has thus far eluded discovery.

Third, as the authors point out, the International Classification of Diseases (ICD) codes for GD are nonspecific and include other lipid disorders. Although the ICD, Ninth Revision code 272.7 is more restrictive, it includes other lysosomal storage diseases such as Fabry disease, which although rarer than GD, should not be discounted, especially among male patients. The ICD, Eighth Revision code 272.2 was substantially less specific and included multiple lipid disorders including hypercholesterolemia. The diagnosis of GD can be validated preferably either by enzyme assay or mutation analysis, or minimally, by comprehensive clinical review.

We believe that a confirmation of the GD cases by direct examination of records is required, and we raise the question as to whether such a validation was done. If not, we propose that this be completed to affirm the validity of the diagnosis of GD, especially in light of our concerns about the lack of specificity of the ICD coding.

Neal J. Weinreb, MD
Hans C. Andersson, MD
Maryam Bankazemi, MD
John Barranger, MD, PhD
Ernest Beutler, MD
Joel Charrow, MD
Gregory A. Grabowski, MD
Carla E. M. Hollak, MD, PhD
Paige Kaplan, MB, BCh
Henry Mankin, MD
Pramod K. Mistry, MD, PhD
Barry E. Rosenbloom, MD
Stephan vom Dahl, MD
Ari Zimran, MD
Clinical diagnostics. Dr. Lewandowski has received grants less than $20,000 from Roche and Dade Behring and speaking honoraria from Roche and Dade Behring.

**Funding/Support:** This study was supported by a grant from the Ed and Maureen Lewis Fund for Cardiology Research, as well as by the Balson Scholar Fund for Cardiovascular Research.

**Additional Information:** Dr. Januzzi is the principal investigator for the NT-ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.

##REFERENCES


